Peptide analogs for treating diseases and disorders
View Patent ↗A peptide having a sequence selected from SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18. Said peptide used for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
1. A method comprising administering to the patient an effective amount of a peptide selected from the group consisting of:
AcCSNLSTCVLGKLSQELHKLQTYPRTDVGANAP-NH2 SEQ ID NO:15,
AcCSNLSTCVLGRLSQELHRLQTFPRTDVGANTAcY SEQ ID NO:12, and
SuccCSNLSTCVLGKLSQELHKLQTYPRTDVGANAY-NH2 SEQ ID NO:17 to effect a weight reduction in the patient.
2. The method of claim 1 , wherein the peptide is formulated for enteral administration.
3. The method of claim 1 , wherein the peptide is formulated for parenteral administration.
4. The method of claim 1 , wherein the peptide is formulated with a carrier for oral administration, and wherein the carrier increases the oral bioavailability of the peptide.
5. The method of claim 4 , wherein the carrier comprises N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), sodium salt of 10-(2-Hydroxybenzamido)decanoic acid (SNAD), or sodium salt of N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAG).
6. The method of claim 1 , wherein the peptide is formulated in a pharmaceutical composition for oral administration comprising coated citric acid particles, and wherein the coated citric acid particles increases the oral bioavailability of the peptide.
7. A method comprising administering to a patient an effective amount of a peptide selected from the group consisting of:
AcCSNLSTCVLGKLSQELHKLQTYPRTDVGANAP-NH2 SEQ ID NO:15,
AcCSNLSTCVLGRLSQELHRLQTFPRTDVGANTAcY SEQ ID NO:12, and
SuccCSNLSTCVLGKLSQELHKLQTYPRTDVGANAY-NH2 SEQ ID NO:17 to effect postprandial glycemic control in the patient.
8. The method of claim 7 , wherein the peptide is formulated for enteral administration.
9. The method of claim 7 , wherein the peptide is formulated for parenteral administration.
10. The method of claim 7 , wherein the peptide is formulated with a carrier for oral administration.
11. The method of claim 10 , wherein the carrier comprises N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), sodium salt of 10-(2-Hydroxybenzamido)decanoic acid (SNAD), or sodium salt of N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAG).
12. The method of claim 7 , wherein the peptide is formulated in a pharmaceutical composition for oral administration comprising coated citric acid particles, and wherein the coated citric acid particles increases the oral bioavailability of the peptide.
13. A method comprising administering to a patient an effective amount of a peptide selected from the group consisting of:
AcCSNLSTCVLGKLSQELHKLQTYPRTDVGANAP-NH2 SEQ ID NO:15,
AcCSNLSTCVLGRLSQELHRLQTFPRTDVGANTAcY SEQ ID NO:12, and
SuccCSNLSTCVLGKLSQELHKLQTYPRTDVGANAY-NH2 SEQ ID NO:17 to effect an improvement in glycemic control in the patient.
14. The method of claim 13 , wherein the peptide is formulated for enteral administration.
15. The method of claim 13 , wherein the peptide is formulated for parenteral administration.
16. The method of claim 12 , wherein the peptide is formulated with a carrier for oral administration.
17. The method of claim 16 , wherein the carrier comprises N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), sodium salt of 10-(2-Hydroxybenzamido)decanoic acid (SNAD), or sodium salt of N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAG).
18. The method of claim 12 , wherein the peptide is formulated in a pharmaceutical composition for oral administration comprising coated citric acid particles, and wherein the coated citric acid particles increases the oral bioavailability of the peptide.